The partnership will help CBSET scale its integrated preclinical research & testing platform through significant capacity expansion and strategic add-on acquisitions Washington, DC – October 1, 2025 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it has completed a majority growth investment in Concord Biomedical […]
GLP study marks a key milestone in Autonomix’s path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a […]
June 17, 2025: The Biotechnology Innovation Organization (BIO) named Massachusetts Governor Maura Healey its 2025 Governor of the Year, recognizing her leadership in advancing biotechnology as a cornerstone of the state’s economy and her commitment to strengthening Massachusetts’s position as a global leader in the field. Since its founding in 2007, CBSET has played a […]
DeepCure Presents Laparoscopic RDN Research Results at CRT 2025 DeepQure, a company specializing in laparoscopic renal denervation (RDN) devices, announced on the 10th that it participated in the Cardiovascular Research Technology (CRT) conference ‘CRT 2025’ held in Washington, D.C., USA on the 8th. CRT 2025 is a globally renowned academic conference in cardiovascular research and […]
DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation SEOUL, South Korea, Oct. 29, 2024 — DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device “HyperQure”. Designed to treat resistant hypertension, HyperQure uses a laparoscopic approach to block the […]
DECODE Network Meeting 5 – “Medical Device Testing during the innovation cycle” – Impressions of an ESR7 by Leo Benolić (ESR7, BioIRC) From April 17th to 19th, 2024, CBSET hosted its fifth network meeting, focusing on “Medical Device Testing during the Innovation Cycle.” The event brought together a diverse group of experts and emerging researchers […]
CBSET welcomes ESR6 Efstathios Stratakos, an early-stage DECODE researcher. About Efstathios Stratakos Host: Politecnico di Milano In silico simulations at macro/meso scale of angioplasty with DCBs, focusing on the mechanical aspects at the balloon-vessel interface (WP3, WP4) Efstathios Stratakos received the Integrated Master’s Degree in Mechanical Engineering and Aeronautics from the University of Patras with […]
CBSET welcomes ESR13 Linnea Tscheuschner, an early-stage DECODE researcher. About Linnea Tscheuschner Host: NKUA Influence of lesion complexity and coating formulation on local coating penetration and downstream embolization after treatment with drug coated balloons (WP3) Linnea Tscheuschner received a master’s degree in Life Science at the University of Hanover, Germany in 2022. Her master’s thesis […]
Peter Markham, CBSET Founder, CEO and President, and Celia Belline, CILcare Founder and CEO discuss “New Medical Approaches to Treating Hearing Loss” In this interview with Hearing Health Matters, Celia and Peter recount their successful strategic collaboration over the last 5 years, and their recent award for their innovative preclinical auditory services in the 3rd […]
LEXINGTON, MA, USA, October 21st, 2022 — CILcare, a leading R&D services company dedicated to ear disorders, announced today that the company, and its partner CBSET Inc., a not-for-profit translational research institute, have been recognized for their innovative preclinical auditory services in the third annual Hearing Technology Innovator Awards™. Through the annual awards program, Hearing […]